Anti-Mouse CD154 - PE

Leinco Technologies
Product Code: LEI-C2351
Product Group: Primary Antibodies
CodeSizePrice
LEI-C2351-50ug50 ug£284.00
Quantity:
LEI-C2351-200ug200 ug£434.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Hamster
Antibody Isotype: IgG
Antibody Clonality: Monoclonal
Antibody Clone: MR1
Regulatory Status: RUO
Target Species: Mouse
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
CD154 is expressed on activated CD4+ T cells.
Concentration:
0.1 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Activated mouse Th1 clone D1.6
Long Description:
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.
NCBI Gene:
21947
Target:
CD154